A joint study by the University of Eastern Finland and Karolinska Institutet in Sweden has found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalisations among individuals with alcohol use disorder (AUD). Fewer hospitalisations were observed for alcohol related causes, substance use related causes and for physical illnesses. However, no association was observed for hospitalisations due to attempted suicide.
The present study examined Swedish registry data on more than 200,000 individuals who had been diagnosed with alcohol use disorder in 2006–2021. Their drug treatments and hospitalisations were followed up until the end of 2023 using the PRE2DUP method developed by the research team and a within-individual design. During the follow-up, 4,321 of the study participants were using semaglutide and 2,509 were using liraglutide.
The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalization due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a 28% lower risk of hospitalization. Both drugs were also associated with a significantly reduced risk of hospitalization due to any substance use disorder: semaglutide with a 32% lower risk, and liraglutide with a 22% lower risk.
The risk of hospitalisation when using GLP-1-agonists was lower than when using naltrexone, which was the most effective drug among drugs already approved for alcohol use disorder. Naltrexone was associated with a 14% lower risk of hospitalisation due to alcohol and substance use related causes.
The use of semaglutide, liraglutide and AUD drugs were all associated with fewer hospitalisations due to physical illness: semaglutide with 22% fewer, liraglutide with 21% fewer and AUD drugs with 15% fewer hospitalisations. No statistically significant association was observed between the use of GLP-1-agonists and hospitalisations due to attempted suicide.
"The research idea stems from patient observations reporting less alcohol consumption since initiating a semaglutide drug. Similar observations have also been highlighted by scientists in international conferences, so we decided to examine this in more detail," explained Docent of Forensic Psychiatry, Markku Lähteenvuo of the University of Eastern Finland and the Niuvanniemi Hospital. "Our study suggests that besides obesity and diabetes, GLP-1-agonists may also help in the treatment of alcohol and substance use disorders; however, these findings need to be further validated in randomized controlled trials.”
The findings were reported in the paper, ‘Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder’, published in JAMA Psychiatry. To access this paper, please click here
ความคิดเห็น